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Seasonal vaccination against malaria: a 
potential use for an imperfect malaria vaccine
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Abstract 
In many parts of the African Sahel and sub‑Sahel, where malaria remains a major cause of mortality and morbidity, 
transmission of the infection is highly seasonal. Seasonal malaria chemoprevention (SMC), which involves administra‑
tion of a full course of malaria treatment to young children at monthly intervals during the high transmission season, 
is proving to be an effective malaria control measure in these areas. However, SMC does not provide complete protec‑
tion and it is demanding to deliver for both families and healthcare givers. Furthermore, there is a risk of the emer‑
gence in the future of resistance to the drugs, sulfadoxine–pyrimethamine and amodiaquine, that are currently being 
used for SMC. Substantial progress has been made in the development of malaria vaccines during the past decade 
and one malaria vaccine, RTS,S/AS01, has received a positive opinion from the European Medicines Authority and will 
soon be deployed in large‑scale, pilot implementation projects in sub‑Saharan Africa. A characteristic feature of this 
vaccine, and potentially of some of the other malaria vaccines under development, is that they provide a high level 
of efficacy during the period immediately after vaccination, but that this wanes rapidly, perhaps because it is difficult 
to develop effective immunological memory to malaria antigens in subjects exposed previously to malaria infection. 
A potentially effective way of using malaria vaccines with high initial efficacy but which provide only a short period 
of protection could be annual, mass vaccination campaigns shortly before each malaria transmission season in areas 
where malaria transmission is confined largely to a few months of the year.
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The seasonality of malaria
Malaria infection shows some degree of seasonal-
ity in nearly all areas where the infection is endemic. 
In extreme cases, for example areas bordering a desert, 
transmission may be limited to only a few weeks in a year 
and occur at irregular intervals. In large parts of Sahelian 
and sub-Sahelian Africa, most transmission occurs dur-
ing just a few months of the year, although there have 
been few observational studies which have recorded in 
detail the incidence of malaria by month of year over a 
period of several years. In tropical Africa, where the tem-
perature is suitable for malaria transmission for most 
of the year, the seasonality of malaria transmission is 
determined largely by seasonal changes in rainfall. By 
comparing the incidence of malaria by month of year 
with the monthly rainfall in areas where both have been 
determined, it has been possible to estimate from rain-
fall patterns, the areas of Africa where malaria is likely 
to be concentrated during 3 or 4 months of the year [1]. 
These lie predominantly in the Sahelian and sub-Sahelian 
regions of Africa (Fig.  1), where the burden of malaria 
continues to be very high.
Seasonal malaria chemoprevention
On the assumption that in areas with highly seasonal 
malaria, it would be necessary to provide protec-
tion against malaria for only a few months of the year 
to obtain highly effective control of clinical malaria, a 
series of trials were conducted in countries of the Sahel 
and sub-Sahel in the 2000s which evaluated the impact 
of providing young children with a treatment course of 
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an effective anti-malarial combination at monthly inter-
vals for three or four months during the peak period of 
malaria transmission. This intervention, known initially 
as intermittent preventive treatment in children (IPTc) 
and now as seasonal malaria chemoprevention (SMC), 
proved highly effective when evaluated in clinical tri-
als, reducing the incidence of uncomplicated malaria 
by 82% (95% CI 75, 87%) and that of severe malaria by 
82% (95% CI 48, 94%), and SMC probably reduced child-
hood deaths [2]. Similar, but slightly lower estimates of 
the degree of protection provided by SMC were obtained 
in a Cochrane review of the efficacy of SMC [3]. On the 
basis of these findings, WHO’s Malaria Policy Advisory 
Committee (MPAC) made a recommendation in 2012 
that SMC with sulfadoxine pyrimethamine (SP) and 
amodiaquine (AQ), given at monthly intervals for 3 or 
4 months, should be introduced into areas of sub-Saha-
ran Africa where malaria transmission is highly seasonal 
and the parasite sensitive to these drugs [4].
Following the provision of financial support from UNI-
TAID and other international donors, SMC is now being 
distributed widely across the Sahel and sub-Sahel with 
a potential annual target of around 20 million children 
[1]. Preliminary results suggest that coverage with SMC 
when rolled out on a large scale through a national pro-
gramme has generally been high [5] although there is 
evidence that coverage declines with later rounds of drug 
administration in some countries. The WHO recommen-
dation on SMC related just to children under the age of 
5  years, but there is recent evidence that in countries, 
such as Senegal, where the main burden of malaria is now 
in older children, SMC given to children under the age of 
10 years is also highly effective and has an indirect ‘herd’ 
effect, reducing the incidence of malaria in older subjects 
who did not receive SMC [6].
SMC is, so far, proving to be a success when imple-
mented on a large scale but sustaining its effective 
delivery will require a long-term commitment from the 
communities where the intervention is being delivered 
from national malaria control programmes and from 
donors. Ensuring that the anti-malarials needed for SMC 
are available at the right time of the year, which may 
vary from year to year depending upon rainfall patterns, 
requires careful planning and logistics. In most large-
scale programmes, SMC is delivered through door-to-
door visits, although in some programmes mothers and 
children are expected to gather at a fixed point in their 
community for drug administration. Twelve contacts per 
year between child and health care worker are required 
if each dose of anti-malarial is to be given under direct 
observation, which is rarely practicable and, if this is not 
done, there is a danger that children will receive only 
their first dose of treatment and not a full course. An 
increase in the proportion of malaria parasites carry-
ing markers of resistance to SP at the end of the malaria 
transmission season was recorded in some of the initial 
trials of SMC [2, 7] and, although there is currently no 
evidence that SMC is failing because of the emergence of 
resistance, this is a potential threat for the future. Cur-
rently, there is no drug combination that could be used to 
replace SP and AQ in the areas where SMC is being deliv-
ered except dihydroartemisinin–piperaquine (DHA–PQ) 
[8], and a decision to use an artemisinin-based combi-
nation therapy on a large scale for chemoprevention in 
Africa would be controversial in view of the threat of the 
emergence and spread of artemisinin and piperaquine 
resistance on the continent. Development of an anti-
malarial with a long action specifically for use in chemo-
prevention in Africa would take several years. For these 
reasons, it is important to consider measures that could 
be used in addition to SMC to control malaria in areas 
where the infection is highly seasonal or, potentially, as 
an alternative.
Progress in malaria vaccine development
There has been considerable progress in malaria vac-
cine development during the past decade. Following a 
large phase 3 trial in seven African countries [9], the pre-
erythrocytic vaccine RTS,S/AS01 has received a positive 
opinion from the European Medicines Agency [10] and 
Fig. 1 A map of sub‑Saharan Africa showing the areas where malaria 
transmission is likely to be highly seasonal. Orange areas indi‑
cate where more than 60% of annual rainfall occurs within 3 months 
of the year, and where malaria incidence is estimated to exceed 100 
cases per 1000 children per year (adapted from Cairns et al. [1])
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will soon be deployed in large-scale, pilot implementa-
tion projects. A second vaccine, the irradiated sporozo-
ites vaccine (PfSPZ), is near to pivotal phase 3 trials [11]. 
Several other pre-erythrocytic and blood stage vaccines 
have shown efficacy in challenge experiments in volun-
teers and in endemic populations but, in general, effi-
cacy has only been limited. A characteristic feature of 
the protection provided by RTS,S/AS01 is its relatively 
short duration. A high level of protection is found dur-
ing the first few months after administration in both 
young children and adults but this wanes rapidly after 
primary immunization [9, 12, 13]. This loss of protection 
is accompanied by a similar rapid decline in antibodies to 
the circumsporozoite antigen (CSP), a partial correlate of 
protection, despite the fact that the vaccine is given with 
a powerful adjuvant. Antibody titres and protection can 
be restored partially by a booster dose of vaccine given 
18 months after primary immunization but the enhanced 
response is again only temporary (Fig.  2) [9, 14]. Little 
information is available about the duration or protection 
provided by other malaria vaccines or about the impact 
of a booster dose. In the case of vaccines based on Plas-
modium falciparum irradiated sporozoites (PfSPZ), or 
on live sporozoites given under cover of anti-malarial 
treatment, it has been shown that some immunized vol-
unteers can sustain protection to challenge with a homol-
ogous strain of parasite for 1 to 2 years [15–17]. However, 
in a recent study conducted in non-immune volunteers, 
the initial high efficacy of PfSPZ against heterologous 
challenge was lost 6 months after vaccination [18]. PfSPZ 
was less efficacious in adult Malian volunteers than in 
American volunteers [19]. Both pre-erythrocytic and 
blood stage vaccines have been developed that use two 
viral vectors given in a prime boost regimen and these 
have provided some protection in both volunteers and 
in the field. Viral-vectored vaccines induce very strong 
T cell response, as measured by ELISPOT, but this T cell 
response declines rapidly in the months following vac-
cination [20, 21] suggesting that vaccines based on this 
delivery system might also provide only a relatively short 
period of protection.
Why it is proving difficult to induce effective immuno-
logical memory and long-term protection with malaria 
vaccines is uncertain. There is recent evidence that pre-
vious exposure to malaria may have an impact on the 
immunological response to subsequent exposure to 
malaria antigens [22] and that this might be mediated 
through generation of atypical B memory cells [23, 24] 
and/or by depletion of T follicular helper cells (Tfh cells) 
which play a key role within germinal centres in facili-
tating the development of immunological memory [25]. 
Thus, in malaria endemic areas, vaccination of young 
children prior to exposure to malaria may be a useful 
approach. However, immune modulation by prior expo-
sure to malaria cannot explain the transitory nature of 
R3C 6-12 weeks;       R3R 6-12 weeks ;         R3C 5-17 months;         R3R 5-17 months  
Vaccinaon Vaccinaon 
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d f
Fig. 2 The transient nature of the protection provided by RTS,S/AS01 and the associated changes in anti‑CSP antibody concentration following 
primary vaccination and administration of a booster dose modelled on the basis of the results of phase 2 and phase 3 RTS,S/AS01 efficacy trials. d 
Shows anti‑CSP antibody titres and f shows the percentage efficacy after primary and booster immunization. Red lines indicate infants vaccinated 
at the age of 6–12 weeks, blue lines those vaccinated at the age of 5–17 months. Dotted lines indicate children who recived a booster dose and solid 
lines those who did not (From White et al. [14])
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the protective immune response seen in non-malaria 
exposed volunteers.
Optimum use of a vaccine providing only a short 
period of protection
It is possible that the next generation of malaria vaccines 
will, like RTS,S/AS01, provide only a relatively short 
period of high-level protection and imperfect immuno-
logical memory. If this proves to be the case, it is impor-
tant to explore situations in which a vaccine with high 
initial efficacy but which cannot provide sustained pro-
tection could be used most effectively. One such situ-
ation is the final stage of an elimination programme, 
provided that the vaccine protected against infection as 
well as clinical malaria. In this case the vaccine, given to 
the whole population, needs to be very safe and effective 
but does not need to provide sustained protection pro-
vided that elimination is achieved. A second use for such 
a vaccine could be pre-empting or halting an epidemic 
caused by an unusual set of environmental or social cir-
cumstances, such as a civil emergency, which is likely to 
be only temporary. A third possibility could be use in 
pregnancy provided the vaccine was shown to be non-
teratogenic. Finally, the vaccine could be used as a sea-
sonal vaccine in areas where a high level of transmission 
is sustained from year to year but is also highly seasonal, 
with the period of maximum risk matching the duration 
of protection provided by the vaccine.
Seasonal malaria vaccination
Influenza provides a paradigm for seasonal vaccination. 
In many industrialized countries, annual influenza vacci-
nation prior to the influenza season is recommended for 
children as well as the elderly and immune-compromised 
[26]. This is necessary because of the need to adjust the 
vaccine to the prevailing strain of virus but also because 
of the poor immunological memory induced by most 
influenza vaccines. A malaria vaccine which provides a 
high level of initial protection but which is of only short 
duration could be used in a similar way to influenza vac-
cines to provide protection to children in areas where the 
peak period of malaria transmission is limited to a few 
months each year and where the burden of infection is 
still high.
Following initial priming of young children, which 
should be undertaken at as early an age as possible, sea-
sonal vaccination could be used either as a supplement 
to SMC in areas where the incidence of malaria remains 
high despite effective delivery of SMC, or as a replace-
ment for SMC if this became necessary due to difficulties 
in sustaining coverage or compliance or because of the 
emergence of drug resistance. Even if efficacy declined 
fairly rapidly after vaccination, it is likely that vaccine 
would, unlike SMC, provide some protection during the 
following dry season when some malaria transmission 
may still occur. Administration of a single dose of vaccine 
through an annual mass campaign directed at children 
under the age of 5 or 10 years may be logistically easier 
than administration of four rounds of treatment each 
year for both health providers and recipients and could 
be as cost effective. Coverage with mass vaccination cam-
paigns, for example with the group A meningitis vaccine 
 MenAfriVacR, in countries of the Sahel has generally 
been very high [27].
In order to test this idea, a trial will be conducted in 
6000 young children in Burkina Faso and Mali which 
will investigate whether priming of young children with 
RTS,S/AS01 followed by a single booster dose at the 
beginning of the two following malaria transmission sea-
sons is non-inferior to SMC with SP and AQ during the 
malaria transmission season, or superior over a whole 
year, and as acceptable and cost effective, and whether 
combination of the two interventions (SMC and RTS,S/
AS01) is superior to either used alone (Fig.  3). The pri-
mary trial end-point will be the incidence of clinical 
malaria detected by passive case detection and there will 
be several secondary end-points. The trial is powered to 
have more than 80% power to exclude a difference of 15% 
in the incidence of clinical malaria over the study period 
between groups. The trial is set to start in 2017 and last 
three years.
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